



ASX Release

## Amendment to Appendix 4E

**Sydney, Wednesday 13 September 2017**

Memphasys (**ASX: MEM, "the Company"**) announces a correction of the Company's Appendix 4E (Preliminary Financial Report) for the year ended 30 June 2017.

### Correction

According to accounting standards, the settlement at mediation on the legal dispute with Transocean Securities Pty Ltd that MEM announced to the market on 8 September 2017 is an adjusting event to be recognised in the financial statements for the year ended 30 June 2017.

### Items in Preliminary Financial Report that changed due to the correction

The adjusting event had an impact on the following items in the Consolidated Statement of Profit or Loss and Other Comprehensive Income, Consolidated Statement of Financial Position and calculation of Earnings per Share:

#### 1- Consolidated Statement of Profit or Loss and Other Comprehensive Income

	Corrected 4E	Initial 4E
<b>Continuing operations</b>		
General & administration	<b>(1,971,689)</b>	(1,750,456)
<b>1.2 Loss before income tax</b>	<b>(1,898,898)</b>	(1,677,665)
<b>1.4 Loss after tax from continuing operations</b>	<b>(1,898,898)</b>	(1,677,665)
<b>1.6 Net loss for the year</b>	<b>(1,999,891)</b>	(1,778,658)
<b>1.7 Net loss attributable to members of parent</b>	<b>(1,999,891)</b>	(1,778,658)
<b>1.9 Total comprehensive expense for the year</b>	<b>(1,999,891)</b>	(1,778,658)

**Memphasys Limited**  
30-32 Richmond Road  
Homebush West NSW 2140

**Postal Address**  
P.O. Box 2202  
Homebush West NSW 2140

**Contact Details**  
**P** +612 8415 7300  
**F** +612 8415 7399

**E** [info@memphasys.com](mailto:info@memphasys.com)  
**W** [memphasys.com](http://memphasys.com)  
**ABN** 33 120 047 556

## 2- Consolidated Statement of Financial Position

	Corrected 4E	Initial 4E
<b>Current assets</b>		
2.2 Trade and other receivables	52,769	119,002
<b>2.5 Total current assets</b>	<b>4,304,114</b>	4,370,347
<b>2.10 Total assets</b>	<b>7,301,690</b>	7,367,923
<b>Current liabilities</b>		
2.11 Trade & other payables	822,000	667,000
<b>2.17 Total current liabilities</b>	<b>6,660,783</b>	6,505,783
<b>2.22 Total liabilities</b>	<b>7,703,930</b>	7,548,930
<b>2.23 Net (liabilities) / assets</b>	<b>(402,240)</b>	(181,007)
<b>Equity</b>		
2.26 Accumulated losses	(37,358,185)	(37,136,952)
<b>2.27 Total equity / (deficiency)</b>	<b>(402,240)</b>	(181,007)

## 3- Earnings per security (EPS)

	Corrected 4E	Initial 4E
6.1 Basic losses per share	(0.34 cents)	(0.30 cents)
6.3 Diluted losses per share	(0.34 cents)	(0.30 cents)

MEM's completed Annual Report will be lodged with the ASX on or before 29 September 2017.

### For further information please contact:

Alison Coutts  
Executive Chairman  
+61 2 8415 7300  
[alison.coutts@memphasys.com](mailto:alison.coutts@memphasys.com)

**About Memphasys:**

Memphasys Limited (**ASX: MEM**) specialises in biological separations for high value commercial applications. The Company's patented membrane processes in combination with electrophoresis, the application of an electrical potential difference across a fluid, enable the separation of high value substances or contaminants from the fluid in which they are contained.

The main application of the technology is the separation of the most viable sperm cells for artificial reproduction, most particularly for human IVF.